MusthInsider

Latest On Protagonist Therapeutics, Inc (PTGX):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-26 01:04 EST	News	Protagonist Therapeutics Sees Steady If Bumpy Progress	N/A
2023-05-24 20:54 EST	News	Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023	N/A
2023-05-12 13:28 EST	News	Protagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseases	N/A
2023-05-05 17:50 EST	News	Protagonist GAAP EPS of -$0.67 in-line	N/A
2023-04-05 11:14 EST	News	Protagonist Therapeutics prices $100M offering	N/A
2023-04-04 19:17 EST	News	Protagonist falls on $100M public offering	N/A
2023-03-16 06:46 EST	News	Protagonist GAAP EPS of -$0.69 misses by $0.10	N/A
2023-03-09 21:16 EST	News	Protagonist Therapeutics: More Good News Likely To Come	N/A
2023-03-07 23:28 EST	News	Johnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidate	N/A
2023-03-07 08:43 EST	News	CDTX, PTGX and TAST among premarket gainers	N/A
2022-11-08 17:47 EST	News	Protagonist GAAP EPS of -$0.64 beats by $0.23	N/A
2022-08-05 06:50 EST	News	Protagonist GAAP EPS of -$0.84 beats by $0.10	N/A
2022-06-15 13:34 EST	News	Protagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - Slideshow	N/A
2022-06-08 23:40 EST	News	Protagonist: Too Many Red Flags	N/A
2022-06-01 03:40 EST	News	Protagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022	N/A
2022-05-05 08:14 EST	News	Protagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65M	N/A
2022-04-26 17:35 EST	News	Protagonist hits 52-week low as Street reacts to data for ulcerative colitis candidate	N/A
2022-04-26 01:38 EST	News	Protagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitis	N/A
2022-04-15 02:54 EST	News	Protagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertide	N/A
2022-03-29 08:38 EST	News	Asif Ali is the new finance chief at Protagonist Therapeutics	N/A
2022-02-28 17:25 EST	News	Protagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62M	N/A
2022-02-01 13:28 EST	News	Protagonist Is Still Being Undervalued Like There's Real Risk	N/A
2021-12-10 01:25 EST	News	Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow	N/A
2021-12-02 23:48 EST	News	Protagonist chooses candidate to advance into phase 2 in collaboration with Janssen	N/A
2021-11-15 11:02 EST	News	Phase 2a data supports Protagonist genetic liver disease drug rusfertide	N/A
2021-10-12 11:34 EST	News	J.P. Morgan upgrades Protagonist to overweight following clinical hold removal	N/A
2021-10-11 16:22 EST	News	Protagonist gains nearly double after FDA removes clinical hold on rusfertide program	N/A
2021-10-11 16:21 EST	News	Protagonist price target raised at Northland following removal of clinical hold	N/A
2021-10-06 15:26 EST	News	PTGX is at high risk of performing badly	N/A
2021-09-30 21:08 EST	News	Protagonist Therapeutics: How To Buy The Dip	N/A
2021-09-28 00:11 EST	News	Warning: PTGX has been downgraded to Very Bearish	N/A
2021-09-25 08:13 EST	News	BELLUS Health, Akoya Biosciences lead weekly healthcare gainers; Protagonist trail	N/A
2021-09-22 04:02 EST	News	Protagonist loses more than half after FDA placed clinical hold on rusfertide studies	N/A
2021-09-22 04:01 EST	News	BELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trail	N/A
2021-09-22 04:00 EST	News	Protagonist extends slide as regulatory setback prompts downgrade at JP Morgan	N/A
2021-09-22 03:59 EST	News	Warning: PTGX has been downgraded to Very Bearish.	N/A
2021-08-10 10:13 EST	News	Protagonist Therapeutics resolves contract dispute with Zealand Pharma	N/A
2021-07-21 20:41 EST	News	Dosing underway in Protagonist Therapeutics' early-stage study of PN-232	N/A
2021-07-21 20:32 EST	News	Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy	N/A
2021-07-21 20:24 EST	News	Protagonist climbs on positive effect in mid-stage study for rusfertide in polycythemia vera	N/A
2021-07-21 20:23 EST	News	Biogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst action	N/A
2021-07-21 20:22 EST	News	Protagonist Therapeutics slumps 7.5% on raising $100M via public offering	N/A
2021-07-21 20:22 EST	News	RAPT, SIOX, ACHL and PTGX among after-hours movers	N/A
2021-07-21 20:21 EST	News	Protagonist Therapeutics secures $115M capital via equity raise	N/A
2021-07-21 20:16 EST	News	Protagonist Therapeutics closes $132M capital raise	N/A
2021-05-05 01:39 EST	News	Protagonist EPS beats by $0.03, beats on revenue	N/A
2021-03-12 04:31 EST	Financials	Company financials have been released.	Neutral
2021-03-12 04:31 EST	Analyst Rating	The Analyst Target Price has increased from $35.4 to $37.	Buy
2021-03-11 12:47 EST	News	Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call Transcript	N/A
2021-03-11 04:23 EST	Earnings Estimate	An EPS average of -$1.48 is estimated for the 2022 year.	Sell

About Protagonist Therapeutics, Inc (PTGX):

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

See Advanced Chart

General

Name Protagonist Therapeutics, Inc
Symbol PTGX
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 79
Fiscal Year EndDecember
IPO Date2016-08-11
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.protagonist-inc.com

Valuation

Price/Sales (Trailing 12 Mt.) 37.31
Price/Book (Most Recent Quarter) 4.86
Enterprise Value Revenue 37.04

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$1.97
Next Year EPS Estimate -$2.12
Next Quarter EPS Estimate -$0.54
Profit Margin -231%
Operating Margin -225%
Return on Assets -17%
Return on Equity -37%
Revenue 28.63 million
Earnings Per Share -$2.74
Revenue Per Share $0.83
Gross Profit 28.63 million
Quarterly Earnings Growth 107.8%

Highlights

Market Capitalization 1.36 billion
EBITDA -70271000
Analyst Target Price $37
Book Value Per Share $6.39

Share Statistics

Shares Outstanding 43.81 million
Shares Float 27.88 million
% Held by Insiders 161%
% Held by Institutions 93.65%
Shares Short 2.77 million
Shares Short Prior Month 2.78 million
Short Ratio 8.34
Short % of Float 7%
Short % of Shares Outstanding 6%

Technicals

Beta 1.55
52 Week High $31.58
52 Week Low $5.44
50 Day Moving Average 26.03
200 Day Moving Average 22.63

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Protagonist Therapeutics, Inc (PTGX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-03-10	$5.65 million	-$0.48	-$0.48	-0.61%
2020-09-30	2020-11-04	$N/A	-$0.21	-$0.61	65.71%
2020-06-30	2020-08-06	$N/A	-$0.59	-$0.57	-2.91%
2020-03-31	2020-05-07	$3.65 million	-$0.72	-$0.69	-4.05%
2019-12-31	2020-03-10	$2.72 million	-$0.63	-$0.65	2.78%
2019-09-30	2019-11-06	$4.14 million	-$0.61	-$0.77	20.26%
2019-06-30	2019-08-07	$-8189000	-$1.18	-$0.39	-206.49%
2019-03-31	2019-05-08	$1.56 million	-$0.58	-$0.56	-4.5%
2018-12-31	2019-03-12	$2.35 million	-$0.57	-$0.47	-20.25%
2018-09-30	2018-11-06	$6.12 million	-$0.38	-$0.37	-1.79%
2018-06-30	2018-08-07	$11.67 million	-$0.41	-$0.30	-35.18%
2018-03-31	2018-05-09	$10.78 million	-$0.36	-$0.24	-50%
2017-12-31	2018-03-07	$11.28 million	-$0.15	-$0.34	55.88%
2017-09-30	2017-11-06	$8.78 million	-$0.29	-$0.81	63.98%
2017-06-30	2017-08-08	$N/A	-$0.89	-$0.86	-4.09%
2017-03-31	2017-05-10	$N/A	-$0.84	-$0.67	-26.32%
2016-12-31	2017-03-07	$N/A	-$0.67	-$0.52	-28.85%
2016-09-30	2016-11-14	$N/A	-$0.87	-$0.64	-35.94%
2016-06-30	2016-07-11	$N/A	-$40.89	-$0.83	-4826.51%

Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Protagonist Therapeutics, Inc (PTGX) Chart:

Protagonist Therapeutics, Inc (PTGX) News:

Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protagonist Therapeutics, Inc (PTGX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2024-12-20	2.5	0	CALL	0	0	392.7	TRUE	0	0
2024-12-20	5	0	CALL	0	0	280.66	TRUE	0	0
2024-12-20	7.5	0	CALL	0	0	222.52	TRUE	0	0
2024-12-20	10	0	CALL	0	0	183.42	TRUE	0	0
2024-12-20	12.5	18.6	CALL	0	30	154.01	TRUE	0	0
2024-12-20	15	8.05	CALL	0	20	135.6	TRUE	0	0
2024-12-20	17.5	11.8	CALL	0	10	110.79	TRUE	0	0
2024-12-20	20	5.6	CALL	0	8	128.41	TRUE	0	0
2024-12-20	22.5	13.5	CALL	0	1	109.03	TRUE	0	0
2024-12-20	25	13.4	CALL	0	4	111.4	TRUE	0	0
2024-12-20	30	8	CALL	0	5	101.12	TRUE	0	0
2024-12-20	35	9	CALL	0	16	94.15	TRUE	0	0
2024-12-20	40	10.7	CALL	0	37	85.87	TRUE	0	0
2024-12-20	45	6.1	CALL	0	23	87.03	FALSE	0	0
2024-12-20	50	4.7	CALL	0	11	81.71	FALSE	0	0
2024-12-20	55	0	CALL	0	0	82.74	FALSE	0	0
2024-12-20	60	2.25	CALL	0	7	85.56	FALSE	0	0
2024-12-20	65	1.7	CALL	0	42	0	FALSE	0	0
2024-12-20	70	0	CALL	0	2	0	FALSE	0	0
2024-12-20	2.5	0	PUT	0	0	0	FALSE	0	0
2024-12-20	5	0	PUT	0	0	0	FALSE	0	0
2024-12-20	7.5	0	PUT	0	0	0	FALSE	0	0
2024-12-20	10	0	PUT	0	0	0	FALSE	0	0
2024-12-20	12.5	0	PUT	0	0	0	FALSE	0	0
2024-12-20	15	0.6	PUT	0	2	0	FALSE	0	0
2024-12-20	17.5	1.05	PUT	0	4	0	FALSE	0	0
2024-12-20	20	1.7	PUT	0	2	0	FALSE	0	0
2024-12-20	22.5	2.1	PUT	0	2	0	FALSE	0	0
2024-12-20	25	0	PUT	0	0	0	FALSE	0	0
2024-12-20	30	1.25	PUT	0	0	0	FALSE	0	0
2024-12-20	35	2.1	PUT	0	3	95.44	FALSE	0	0
2024-12-20	40	2.35	PUT	0	3	84.82	FALSE	0	0
2024-12-20	45	4.4	PUT	0	2	80.99	TRUE	0	0
2024-12-20	50	0	PUT	0	0	76.06	TRUE	0	0
2024-12-20	55	0	PUT	0	0	90.16	TRUE	0	0
2024-12-20	60	0	PUT	0	0	79.02	TRUE	0	0
2024-12-20	65	0	PUT	0	0	77.96	TRUE	0	0
2024-12-20	70	0	PUT	0	0	92.08	TRUE	0	0
2025-01-17	15	0	CALL	0	0	124.96	TRUE	0	0
2025-01-17	17.5	0	CALL	0	0	123.12	TRUE	0	0
2025-01-17	20	0	CALL	0	0	96.71	TRUE	0	0
2025-01-17	22.5	14.9	CALL	0	20	111.69	TRUE	0	0
2025-01-17	25	12.8	CALL	0	20	107.07	TRUE	0	0
2025-01-17	30	16.7	CALL	0	7	99.38	TRUE	0	0
2025-01-17	35	12.7	CALL	0	5	94.01	TRUE	0	0
2025-01-17	40	11.25	CALL	0	1	91.85	TRUE	0	0
2025-01-17	45	6.5	CALL	0	42	84.92	FALSE	0	0
2025-01-17	50	5.48	CALL	0	6	86.97	FALSE	0	0
2025-01-17	55	5.1	CALL	0	6	81.84	FALSE	0	0
2025-01-17	60	0	CALL	0	0	82.81	FALSE	0	0
2025-01-17	65	3	CALL	0	17	81.43	FALSE	0	0
2025-01-17	70	2.1	CALL	0	8	0	FALSE	0	0
2025-01-17	15	0	PUT	0	0	0	FALSE	0	0
2025-01-17	17.5	0	PUT	0	0	0	FALSE	0	0
2025-01-17	20	0	PUT	0	0	0	FALSE	0	0
2025-01-17	22.5	0	PUT	0	0	0	FALSE	0	0
2025-01-17	25	0	PUT	0	0	0	FALSE	0	0
2025-01-17	30	1.5	PUT	0	5	0	FALSE	0	0
2025-01-17	35	0	PUT	0	0	86.48	FALSE	0	0
2025-01-17	40	0	PUT	0	0	97.48	FALSE	0	0
2025-01-17	45	0	PUT	0	0	91.14	TRUE	0	0
2025-01-17	50	0	PUT	0	0	76.26	TRUE	0	0
2025-01-17	55	0	PUT	0	0	85.08	TRUE	0	0
2025-01-17	60	0	PUT	0	0	87.64	TRUE	0	0
2025-01-17	65	0	PUT	0	0	86.29	TRUE	0	0
2025-01-17	70	0	PUT	0	0	76.99	TRUE	0	0
2025-04-17	22.5	20.85	CALL	0	20	91.45	TRUE	0	0
2025-04-17	25	18.75	CALL	0	20	96.91	TRUE	0	0
2025-04-17	30	0	CALL	0	0	90.37	TRUE	0	0
2025-04-17	35	15.6	CALL	0	3	93.11	TRUE	0	0
2025-04-17	40	0	CALL	0	0	86.69	TRUE	0	0
2025-04-17	45	10.1	CALL	0	11	85.71	FALSE	0	0
2025-04-17	50	8.21	CALL	0	21	79.97	FALSE	0	0
2025-04-17	55	7.6	CALL	0	14	75.67	FALSE	0	0
2025-04-17	60	0	CALL	0	0	79.05	FALSE	0	0
2025-04-17	65	0	CALL	0	0	80.11	FALSE	0	0
2025-04-17	70	0	CALL	0	7	78.34	FALSE	0	0
2025-04-17	22.5	2.4	PUT	0	1	0	FALSE	0	0
2025-04-17	25	2.9	PUT	0	2	0	FALSE	0	0
2025-04-17	30	4	PUT	0	1	83.53	FALSE	0	0
2025-04-17	35	4.7	PUT	2	597	78	FALSE	4.7	0
2025-04-17	40	7.4	PUT	0	300	84.31	FALSE	0	0
2025-04-17	45	9.8	PUT	4	44	77.34	TRUE	0.1	0.01
2025-04-17	50	12.9	PUT	0	1	82.94	TRUE	0	0
2025-04-17	55	0	PUT	0	0	79.09	TRUE	0	0
2025-04-17	60	19.4	PUT	0	2	78.63	TRUE	0	0
2025-04-17	65	0	PUT	0	0	77.11	TRUE	0	0
2025-04-17	70	0	PUT	0	0	81.74	TRUE	0	0
2025-07-18	22.5	0	CALL	0	0	85.36	TRUE	0	0
2025-07-18	25	0	CALL	0	0	84.19	TRUE	0	0
2025-07-18	30	16.5	CALL	0	0	82.73	TRUE	0	0
2025-07-18	35	0	CALL	0	0	79.07	TRUE	0	0
2025-07-18	40	0	CALL	0	0	77.91	TRUE	0	0
2025-07-18	45	12.9	CALL	0	5	78.71	FALSE	0	0
2025-07-18	50	0	CALL	0	0	75.26	FALSE	0	0
2025-07-18	55	0	CALL	0	0	68.5	FALSE	0	0
2025-07-18	60	5	CALL	0	23	72.08	FALSE	0	0
2025-07-18	65	6.7	CALL	0	2	70.93	FALSE	0	0
2025-07-18	70	0	CALL	0	0	71.99	FALSE	0	0
2025-07-18	22.5	0	PUT	0	0	0	FALSE	0	0
2025-07-18	25	0	PUT	0	0	0	FALSE	0	0
2025-07-18	30	0	PUT	0	0	74.63	FALSE	0	0
2025-07-18	35	6.3	PUT	0	15	81.78	FALSE	0	0
2025-07-18	40	0	PUT	0	0	75.78	FALSE	0	0
2025-07-18	45	0	PUT	0	0	69.44	TRUE	0	0
2025-07-18	50	12.6	PUT	0	10	72.56	TRUE	0	0
2025-07-18	55	0	PUT	0	0	70.53	TRUE	0	0
2025-07-18	60	21	PUT	2	0	71.08	TRUE	21	0
2025-07-18	65	0	PUT	0	0	71.62	TRUE	0	0
2025-07-18	70	0	PUT	0	0	67.33	TRUE	0	0

Latest PTGX Trades:

Date	Shares	Price
Jun 13, 2022 7:59 PM EST	13	$7.08
Jun 13, 2022 7:59 PM EST	8	$7.07
Jun 13, 2022 7:59 PM EST	1	$7.07
Jun 13, 2022 7:59 PM EST	14	$7.07
Jun 13, 2022 7:59 PM EST	34	$7.09

Protagonist Therapeutics, Inc (PTGX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Date	Form Type	Form Name	Link
2020-06-09	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2018-09-18	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1377121/000000000018029279/0000000000-18-029279-index.htm
2019-11-21	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1377121/000000000019015720/0000000000-19-015720-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000031506619001298/0000315066-19-001298-index.htm
2020-02-07	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000031506620001141/0000315066-20-001141-index.htm
2020-02-07	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000083423720008027/0000834237-20-008027-index.htm
2020-06-09	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000090266419000928/0000902664-19-000928-index.htm
2020-05-22	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000090266420002197/0000902664-20-002197-index.htm
2018-08-10	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000092189518002281/0000921895-18-002281-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000092189519000465/0000921895-19-000465-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000092189520000521/0000921895-20-000521-index.htm
2018-07-02	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000093041318002140/0000930413-18-002140-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000093041319000575/0000930413-19-000575-index.htm
2018-08-07	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1377121/000104746918005447/0001047469-18-005447-index.htm
2018-09-07	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/0001047469-18-006015-index.htm
2018-09-26	424B3	Prospectus [Rule 424(b)(3)]	https://www.sec.gov/Archives/edgar/data/1377121/000104746918006444/0001047469-18-006444-index.htm
2019-04-26	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1377121/000104746919002642/0001047469-19-002642-index.htm
2019-10-31	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1377121/000104746919006014/0001047469-19-006014-index.htm
2019-11-27	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1377121/000104746919006551/0001047469-19-006551-index.htm
2020-04-16	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1377121/000104746920002368/0001047469-20-002368-index.htm
2020-05-11	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1377121/000104746920002943/0001047469-20-002943-index.htm
2020-05-13	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1377121/000104746920003025/0001047469-20-003025-index.htm
2018-08-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918049635/0001104659-18-049635-index.htm
2018-08-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/0001104659-18-049963-index.htm
2018-09-20	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1377121/000110465918057889/0001104659-18-057889-index.htm
2018-10-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918063178/0001104659-18-063178-index.htm
2018-11-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918066340/0001104659-18-066340-index.htm
2018-11-27	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918070107/0001104659-18-070107-index.htm
2018-12-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/0001104659-18-075322-index.htm
2019-03-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919014250/0001104659-19-014250-index.htm
2019-03-12	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1377121/000110465919014317/0001104659-19-014317-index.htm
2019-03-25	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919017130/0001104659-19-017130-index.htm
2019-04-26	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1377121/000110465919024116/0001104659-19-024116-index.htm
2019-05-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919027659/0001104659-19-027659-index.htm
2019-05-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919027662/0001104659-19-027662-index.htm
2019-05-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919029003/0001104659-19-029003-index.htm
2019-05-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/0001104659-19-032445-index.htm
2019-06-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919035338/0001104659-19-035338-index.htm
2019-06-17	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000110465919035942/0001104659-19-035942-index.htm
2019-08-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919044426/0001104659-19-044426-index.htm
2019-10-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919058437/0001104659-19-058437-index.htm
2019-11-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919060537/0001104659-19-060537-index.htm
2019-11-20	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1377121/000110465919065981/0001104659-19-065981-index.htm
2019-11-27	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/0001104659-19-068332-index.htm
2019-12-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465919069217/0001104659-19-069217-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000110465920021728/0001104659-20-021728-index.htm
2020-02-24	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/0001104659-20-024253-index.htm
2020-03-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920031381/0001104659-20-031381-index.htm
2020-03-10	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1377121/000110465920031453/0001104659-20-031453-index.htm
2020-03-18	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920035420/0001104659-20-035420-index.htm
2020-04-16	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1377121/000110465920047714/0001104659-20-047714-index.htm
2020-05-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920058140/0001104659-20-058140-index.htm
2020-05-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920059922/0001104659-20-059922-index.htm
2020-05-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920067747/0001104659-20-067747-index.htm
2020-06-08	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1377121/000110465920070830/0001104659-20-070830-index.htm
2020-08-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920091424/0001104659-20-091424-index.htm
2020-08-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920094719/0001104659-20-094719-index.htm
2020-09-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920104437/0001104659-20-104437-index.htm
2020-10-02	8-K/A	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920111763/0001104659-20-111763-index.htm
2020-11-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000110465920121408/0001104659-20-121408-index.htm
2018-12-10	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000119312518345594/0001193125-18-345594-index.htm
2019-01-24	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000119312519015661/0001193125-19-015661-index.htm
2019-02-05	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000119312519028285/0001193125-19-028285-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000119312519040996/0001193125-19-040996-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000119312520038117/0001193125-20-038117-index.htm
2018-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118037316/0001209191-18-037316-index.htm
2018-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/0001209191-18-037317-index.htm
2018-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/0001209191-18-037318-index.htm
2018-07-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118042575/0001209191-18-042575-index.htm
2018-08-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2018-08-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2018-08-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-01-09	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119003141/0001209191-19-003141-index.htm
2019-01-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-01-14	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119003645/0001209191-19-003645-index.htm
2019-01-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/0001209191-19-003994-index.htm
2019-02-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2019-02-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-02-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-03-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-03-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-03-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-03-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-03-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-04-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119022776/0001209191-19-022776-index.htm
2019-04-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2019-05-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/0001209191-19-030616-index.htm
2019-06-03	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119034081/0001209191-19-034081-index.htm
2019-06-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119034082/0001209191-19-034082-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036195/0001209191-19-036195-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036203/0001209191-19-036203-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036204/0001209191-19-036204-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036207/0001209191-19-036207-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/0001209191-19-036211-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/0001209191-19-036214-index.htm
2019-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-11-27	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-12-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2019-12-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-12-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm
2020-02-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/0001209191-20-014088-index.htm
2020-02-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120014090/0001209191-20-014090-index.htm
2020-02-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/0001209191-20-014092-index.htm
2020-02-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120014097/0001209191-20-014097-index.htm
2020-02-28	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/0001209191-20-014100-index.htm
2020-03-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2020-03-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2020-04-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120023949/0001209191-20-023949-index.htm
2020-05-01	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120026593/0001209191-20-026593-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033016/0001209191-20-033016-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033020/0001209191-20-033020-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033022/0001209191-20-033022-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033026/0001209191-20-033026-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/0001209191-20-033031-index.htm
2020-05-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/0001209191-20-033032-index.htm
2020-08-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2020-08-18	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120047233/0001209191-20-047233-index.htm
2020-08-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1377121/000120919120047246/0001209191-20-047246-index.htm
2018-08-20	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000121465918005609/0001214659-18-005609-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000121465919001113/0001214659-19-001113-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000121465920001392/0001214659-20-001392-index.htm
2019-07-01	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000131924419000056/0001319244-19-000056-index.htm
2019-12-16	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000149315219019237/0001493152-19-019237-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1377121/000149315220002364/0001493152-20-002364-index.htm
2018-08-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1377121/000155837018006590/0001558370-18-006590-index.htm
2018-08-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/0001558370-18-006639-index.htm
2018-11-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837018008657/0001558370-18-008657-index.htm
2019-03-12	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1377121/000155837019001853/0001558370-19-001853-index.htm
2019-05-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/0001558370-19-004481-index.htm
2019-08-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/0001558370-19-007515-index.htm
2019-11-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/0001558370-19-010201-index.htm
2020-03-10	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/0001558370-20-002334-index.htm
2020-05-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837020005785/0001558370-20-005785-index.htm
2020-08-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/0001558370-20-009681-index.htm
2020-11-04	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1377121/000155837020012597/0001558370-20-012597-index.htm
2018-09-21	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1377121/999999999518002437/9999999995-18-002437-index.htm
2019-11-22	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1377121/999999999519002648/9999999995-19-002648-index.htm

Protagonist Therapeutics, Inc (PTGX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2020-08-11	CHAITAN PHD KHOSLA	Director	Sell	2,499.00	17.19	42,952.06	0.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-12-03	Donald A. Kalkofen	Chief Financial Officer	Buy	562.00	5.09	2,860.58	1,175.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2020-03-12	HAROLD E SELICK	Director	Buy	12,000.00	6.70	80,400.00	15,310.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2019-02-28	Suneel Gupta	EVP Clinical Operations	Buy	7,500.00			17,500.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-02-06	Richard S. Shames	Chief Medical Officer	Sell	2,580.00	7.71	19,891.80	24,178.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2020-08-11	CHAITAN PHD KHOSLA	Director	Buy	2,499.00	1.89	4,723.11	2,499.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-02-28	Samuel R Saks	Chief Development Officer	Buy	2,500.00			2,500.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-02-06	Richard S. Shames	Chief Medical Officer	Sell	198.00	8.15	1,613.70	26,758.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2018-08-15	Richard S. Shames	Chief Medical Officer	Buy	18,750.00			26,956.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-15	Thomas P. O'Neil	Chief Financial Officer	Buy	21,100.00			30,560.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-03-01	Richard S. Shames	Chief Medical Officer	Sell	657.00	8.03	5,275.71	32,021.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-02-28	Richard S. Shames	Chief Medical Officer	Buy	8,500.00			32,678.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-04-01	HAROLD E SELICK	Director	Buy	3,310.00	1.31	4,336.10	3,310.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2018-08-15	DINESH V PH D PATEL	President and CEO	Buy	82,050.00			345,829.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2019-02-06	DINESH V PH D PATEL	President and CEO	Sell	10,132.00	7.71	78,117.72	357,264.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-02-06	DINESH V PH D PATEL	President and CEO	Sell	777.00	8.10	6,292.22	367,396.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-01-11	DINESH V PH D PATEL	President and CEO	Buy	22,344.00	1.16	25,919.04	368,173.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-02-06	David Y Liu	Chief Scientific Officer	Sell	3,821.00	7.74	29,561.55	37,007.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-08-06	DINESH V PH D PATEL	President and CEO	Sell	10,792.00	8.85	95,535.10	374,792.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-11-26	DINESH V PH D PATEL	President and CEO	Buy	4,000.00	1.16	4,640.00	379,824.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-03-01	DINESH V PH D PATEL	President and CEO	Sell	2,183.00	8.03	17,529.49	383,831.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-02-28	DINESH V PH D PATEL	President and CEO	Buy	28,750.00			386,014.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-12-03	DINESH V PH D PATEL	President and CEO	Buy	10,000.00	5.55	55,500.00	389,824.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2018-08-15	David Y Liu	Chief Scientific Officer	Buy	25,800.00			40,828.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2019-12-03	DINESH V PH D PATEL	President and CEO	Buy	20,000.00	5.65	113,000.00	409,824.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2020-03-12	DINESH V PH D PATEL	President and CEO	Buy	18,344.00	1.16	21,279.04	429,990.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-20	DINESH V PH D PATEL	President and CEO	Buy	10,000.00	1.89	18,900.00	439,990.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2019-12-03	Suneel Gupta	EVP Clinical Operations	Buy	30,000.00	5.13	153,900.00	49,500.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-08-06	David Y Liu	Chief Scientific Officer	Sell	3,395.00	8.85	30,044.05	49,802.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-03-01	David Y Liu	Chief Scientific Officer	Sell	810.00	8.03	6,504.30	51,197.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-02-28	David Y Liu	Chief Scientific Officer	Buy	15,000.00			52,007.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-12-03	Donald A. Kalkofen	Chief Financial Officer	Buy	613.00	5.10	3,126.30	613.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03	Bryan Giraudo	Director	Buy	8,000.00	5.70	45,620.00	8,000.00	https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm

Protagonist Therapeutics, Inc

(NASDAQ:PTGX)